Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Target ID: TTDS00018

Target Information
NameGamma-aminobutyric acid receptor    
Type of targetSuccessful target    
SynonymsGABA receptor    
DiseaseAnxiety disorder, unspecified
[ICD9: 300   ICD10: F40-F42]
[1]
Helminth infection
[ICD9: 001-139   ICD10: A00-B99]
[2]
Huntington's disease
[ICD9: 294.1, 333.4   ICD10: F02.2, G10]
[3]
Hypertonia and apnoeic episodes[4]
Mood [affective] disorders[5]
Parkinson's disease
[ICD9: 332   ICD10: F02.3, G20]
[6]
Drug(s)ClonazepamApprovedEpilepsy[7][4]
PhenobarbitalApprovedSeizures[8][9]
PiperazineApprovedAscariasis and enterobiasis[2]
Phentermine+topiramatePhase IIIObesity[10]
BL-1020Phase II completedSchizophrenia[11]
GanaxolonePhase II completedEpilepsy[12][13][14]
DextofisopamPhase IIIrritable bowel syndrome[15]
PhenylbutyratePhase IIUrea cycle disorders[16]
RG1662Phase ICognitive disorders in patients with Down's syndrome
E-2007Terminated in Phase IIIParkinsoní»s disease[17][18]
BioChemical ClassChloride channel    
PathwayNeuroactive ligand-receptor interaction
Target ValidationClick to Find Target Validation Information.    
Inhibitor (4R)-4-ammoniopentanoate[19]
(4S)-4-ammoniopentanoate[19]
AFLATREME[20]
ALFAXALONE[21]
ALLOPREGNANOLONE[22]
ALPIDEM[23]
AMENTOFLAVONE[24]
ANDROSTERONE[22]
BETA-CCM[25]
BRL-54504AX[26]
CGP-27492[27]
CGS-13767[28]
CGS-17867A[29]
CGS-8216[28]
CGS-9895[30]
CGS-9896[31]
CI-218872[32]
DIAZEPAM HYDROCHLORIDE[33]
Divaplon[34]
ELTANOLONE[22]
ETIOCHOLANOLONE[22]
GABAZINE[35]
GABAZINE[36]
GAMMA-AMINO-BUTANOIC ACID[37]
GNF-PF-3645[38]
GNF-PF-4421[38]
NIPECOTIC ACID[39]
NORHARMANE[40]
NSC-19028[41]
NSC-73613[42]
NSC-93394[42]
PITRAZEPINE[43]
PNU-91571[44]
Piperidine-4-carboxylic acid[45]
Pyrrolidin-3-yl-acetic acid[39]
RIPAZEPAM[46]
RO-054520[47]
RO-145974[48]
RO-145975[48]
RO-147437[48]
RO-194603[48]
RWJ-16979[49]
RY-066[50]
Ro-15-3505,   Sarmazenil[51]
Ro-151310[52]
Ro-154513[53]
Ro-16-6028[54]
Ro-4882224[55]
Ro-4938581[55]
THIOCOLCHICOSIDE[37]
TPA-023[56]
Toluene-1-diazonium-3-sulfonic acid anion[57]
U-78875[44]
U-89267[58]
WEDELOLACTONE[59]
ZK-93423[60]
ridine-5-carboxylic acid ethyl ester[61]
AgonistBL-1020[11]
Clonazepam[7][4]
Dextofisopam[15]
E-2007[17][18]
Muscimol[3]
Phenylbutyrate[16]
AntagonistBicuculline[1]
Clomethiazole[62]
Phenobarbital[8][9]
Piperazine[2]
SR95531[1]
ModulatorGabapentin GR[63]
Ganaxolone[12][13][14]
Phentermine+topiramate[10]
MultitargetBL-1020[11]
Dextofisopam[15]
Phentermine+topiramate[10]
Phenylbutyrate[16]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1GABA receptors inhibited by benzodiazepines mediate fast inhibitory transmission in the central amygdala. J Neurosci. 1999 Nov 15;19(22):9698-704. To Reference
Ref 2Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents. 2003 Sep;22(3):318-31. To Reference
Ref 3THIP treatment of Huntington's disease. Neurology. 1983 May;33(5):637-9. To Reference
Ref 4Hyperekplexia in neonates. Postgrad Med J. 2001 Sep;77(911):570-2. To Reference
Ref 5Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry. 2002;7 Suppl 1:S71-80. To Reference
Ref 6GABA receptor agonists and extrapyramidal motor function: therapeutic implications for Parkinson's disease. Adv Neurol. 1987;45:79-83. To Reference
Ref 7Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. To Reference
Ref 8DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. Epub 2007 Nov 29. To Reference
Ref 9Anticonvulsant drugs: mechanisms of action. Adv Neurol. 1986;44:713-36. To Reference
Ref 10Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. To Reference
Ref 11The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. To Reference
Ref 12Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22. To Reference
Ref 13Epilepsy Res. 2009 Jan;83(1):1-43. Epub 2008 Nov 12.Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). To Reference
Ref 14New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs. 2006 Jun;15(6):637-47. To Reference
Ref 15Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. To Reference
Ref 16Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. To Reference
Ref 17Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. To Reference
Ref 18Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54. To Reference
Ref 19J Med Chem. 1981 Dec;24(12):1377-83.gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. To Reference
Ref 20Bioorg. Med. Chem. Lett. 5(3):265-270 (1995) To Reference
Ref 21J Med Chem. 1998 May 21;41(11):1846-54.Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological profile at recombinant human GABAA receptors. To Reference
Ref 22J Med Chem. 2006 Jul 27;49(15):4595-605.Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. To Reference
Ref 23J Med Chem. 1997 Sep 12;40(19):3109-18.Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new series of high-affinity and selective ligands for the peripheral type. To Reference
Ref 24Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4.Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. To Reference
Ref 25J Med Chem. 1995 Jan 6;38(1):189-98.Synthetic routes to 4-amino-3-carboxy-beta-carboline derivatives: incidental formation of novel furo[3,4-c]-beta-carbolin-2-ones displaying high affinities for the benzodiazepine receptor. To Reference
Ref 26Bioorg. Med. Chem. Lett. 5(22):2589-2592 (1995) To Reference
Ref 27J Med Chem. 1995 Aug 18;38(17):3297-312.Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. To Reference
Ref 28J Med Chem. 1991 Jan;34(1):281-90.Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones. To Reference
Ref 29Bioorg Med Chem Lett. 2004 Jul 5;14(13):3441-4.2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor. To Reference
Ref 30J Med Chem. 1987 Oct;30(10):1737-42.1,3-Diarylpyrazolo[4,5-c]- and -[5,4-c]quinolin-4-ones. 4. Synthesis and specific inhibition of benzodiazepine receptor binding. To Reference
Ref 31J Med Chem. 2006 Mar 23;49(6):1855-66.Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. To Reference
Ref 32Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. Epub 2010 Sep 29.Design, synthesis, and subtype selectivity of 3,6-disubstituted Ž┬-carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents for treatment of alcohol abuse. To Reference
Ref 33J Med Chem. 1992 Oct 30;35(22):4105-17.Molecular yardsticks. Rigid probes to define the spatial dimensions of the benzodiazepine receptor binding site. To Reference
Ref 34J Med Chem. 1988 Jun;31(6):1220-6.(Imidazo[1,2-a]pyrimidin-2-yl)phenylmethanones and related compounds as potential nonsedative anxiolytics. To Reference
Ref 35J Med Chem. 2006 Feb 23;49(4):1388-96.Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. To Reference
Ref 36J Med Chem. 2005 Jan 27;48(2):427-39.Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. To Reference
Ref 37J Med Chem. 2006 Sep 7;49(18):5571-7.3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. To Reference
Ref 38J Med Chem. 2006 Apr 20;49(8):2526-33.4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore modeling. To Reference
Ref 39J Med Chem. 1985 May;28(5):653-60.Orally active and potent inhibitors of gamma-aminobutyric acid uptake. To Reference
Ref 40J Med Chem. 1988 Sep;31(9):1854-61.Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. To Reference
Ref 41J Med Chem. 2002 Sep 12;45(19):4188-201.Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. To Reference
Ref 42Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997) To Reference
Ref 43J Med Chem. 1992 May 29;35(11):1969-77.Structure and molecular modeling of GABAA receptor antagonists. To Reference
Ref 44J Med Chem. 1999 Apr 8;42(7):1123-44.Piperazine imidazo[1,5-a]quinoxaline ureas as high-affinity GABAA ligands of dual functionality. To Reference
Ref 45J Med Chem. 1982 Oct;25(10):1157-62.Hydroxy- and amino-substituted piperidinecarboxylic acids as gamma-aminobutyric acid agonists and uptake inhibitors. To Reference
Ref 46J Med Chem. 1985 May;28(5):683-5.Synthesis and interaction of 5-(substituted-phenyl)-3-methyl-6,7-dihydropyrazolo[4,3-e] [1,4]diazepin-8(7H)-ones with benzodiazepine receptors in rat cerebral cortex. To Reference
Ref 47J Med Chem. 1988 Dec;31(12):2235-46.Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. To Reference
Ref 48J Med Chem. 1993 Apr 16;36(8):1001-6.Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepine receptors. To Reference
Ref 49J Med Chem. 1995 Jan 6;38(1):16-20.Potential anxiolytic agents. Pyrido[1,2-a]benzimidazoles: a new structural class of ligands for the benzodiazepine binding site on GABA-A receptors. To Reference
Ref 50J Med Chem. 1998 Oct 8;41(21):4130-42.Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines at five recombinant GABAA/benzodiazepine receptor subtypes [alphaxbeta3gamma2 (x = 1-3, 5, and 6)] via comparative molecular field analysis. To Reference
Ref 51J Med Chem. 1995 May 12;38(10):1679-88.Synthesis of novel imidazobenzodiazepines as probes of the pharmacophore for "diazepam-insensitive" GABAA receptors. To Reference
Ref 52Bioorg Med Chem. 2010 Nov 15;18(22):7731-8. Epub 2010 Jun 1.The GABA(A) receptor as a target for photochromic molecules. To Reference
Ref 53J Med Chem. 1996 Apr 26;39(9):1928-34.Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABAA receptors. To Reference
Ref 54J Med Chem. 1997 Jan 3;40(1):61-72.Synthesis and in vitro activity of 3 beta-substituted-3 alpha-hydroxypregnan-20-ones: allosteric modulators of the GABAA receptor. To Reference
Ref 55Bioorg Med Chem Lett. 2009 Oct 15;19(20):5940-4. Epub 2009 Aug 15.The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment of cognitive dysfunction. To Reference
Ref 56J Med Chem. 2005 Nov 17;48(23):7089-92.7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models. To Reference
Ref 57J Med Chem. 1987 Dec;30(12):2222-7.Aryl diazo compounds and diazonium salts as potential irreversible probes of the gamma-aminobutyric acid receptor. To Reference
Ref 58J Med Chem. 1994 Mar 18;37(6):758-68.Antagonist, partial agonist, and full agonist imidazo[1,5-a]quinoxaline amides and carbamates acting through the GABAA/benzodiazepine receptor. To Reference
Ref 59Bioorg Med Chem Lett. 2001 Feb 12;11(3):283-6.Synthesis and preliminary pharmacological evaluation of coumestans with different patterns of oxygenation. To Reference
Ref 60J Med Chem. 1990 Mar;33(3):1062-9.Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester. To Reference
Ref 61J Med Chem. 1989 Dec;32(12):2561-73.Synthesis and structure-activity relationships of a series of anxioselective pyrazolopyridine ester and amide anxiolytic agents. To Reference
Ref 62Current status of neuroprotective agents in the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2001 Jan;1(1):13-8. To Reference
Ref 63Emerging therapies for neuropathic pain. Expert Opin Emerg Drugs. 2005 Feb;10(1):95-108. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543